In vitro disease models that could lead to new therapies
New models can help researchers investigate disease development and find new treatment approaches.
PromoCell - a manufacturer of human primary cells and cell culture products - now offers cell disease models covering a wide range of diseases including diabetes type 1 and 2, respiratory diseases such as COPD and asthma, as well as cardiomyopathy disease.
Relevant models enable experiments under physiologic conditions and are key for developing new therapies for chronic diseases. With its greater range of cell disease models, PromoCell once again underlines its role as a dedicated supporter of scientific research and innovation.
Large selection of donor cells with known disease status
“PromoCell now offers a large selection of donor cells with known disease status that are suitable for drug discovery and research applications,” says Daniel Spatz, CBO of PromoCell. These disease cell types can be cultured using PromoCell’s matching growth media to ensure optimal growth performance. “Our diseased cells feature the same specifications and undergo the same rigid quality control tests as their healthy counterparts from our human primary cell portfolio,” adds Dr. Irma Boercsoek, COO of PromoCell. The tests include cell factors marker characterization, growth performance and morphology.
Developing and testing potential treatment approaches
A cell disease model is an in vitro culture of cells isolated from a tissue donor with a known disease condition. By studying cell disease models, researchers gain insights in how diseases develop and this also enables them to look for new molecular targets for specific therapies. In addition, cell disease models can be used for testing potential treatment approaches. With its comprehensive portfolio of products and services for human cell culture, PromoCell supports scientists worldwide in advancing research and developing safer drugs.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance